NuVasive (NUVA) Stock Forecast, Price & News

NuVasive (NASDAQ:NUVA) Frequently Asked Questions

Is NuVasive a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NuVasive stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUVA, but not buy additional shares or sell existing shares.
View analyst ratings for NuVasive or view top-rated stocks.

When is NuVasive's next earnings date?

NuVasive is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for NuVasive.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) announced its earnings results on Wednesday, May, 4th. The medical device company reported $0.54 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.16. The medical device company had revenue of $290.80 million for the quarter, compared to analysts' expectations of $277.63 million. NuVasive had a positive trailing twelve-month return on equity of 11.85% and a negative net margin of 3.23%. The firm's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.37 EPS.
View NuVasive's earnings history.

How will NuVasive's stock buyback program work?

NuVasive declared that its Board of Directors has initiated a share repurchase program on Tuesday, November 9th 2021, which permits the company to buyback $100,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase up to 3.5% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board of directors believes its stock is undervalued.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive updated its FY 2022 earnings guidance on Wednesday, May, 11th. The company provided earnings per share guidance of $2.15-$2.45 for the period, compared to the consensus earnings per share estimate of $2.17. The company issued revenue guidance of $1.21 billion-$1.23 billion, compared to the consensus revenue estimate of $1.21 billion.

What price target have analysts set for NUVA?

11 brokers have issued 12-month price objectives for NuVasive's stock. Their forecasts range from $54.00 to $83.00. On average, they anticipate NuVasive's stock price to reach $63.78 in the next twelve months. This suggests a possible upside of 17.9% from the stock's current price.
View analysts' price targets for NuVasive or view top-rated stocks among Wall Street analysts.

Who are NuVasive's key executives?

NuVasive's management team includes the following people:

• Mr. J. Christopher Barry, CEO & Director (Age 48, Pay $2.93M) (LinkedIn Profile)
• Mr. Matthew K. Harbaugh, Exec. VP & CFO (Age 52, Pay $939.39k)
• Mr. Dale A. Wolf, Sr. VP of Global Operations (Age 42, Pay $679.16k)
• Mr. Nathaniel B. Sisitsky Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 47, Pay $787.93k)
• Mr. Massimo Calafiore, Exec. VP & Chief Commercial Officer (LinkedIn Profile)
• Mr. Ryan Donahoe, Sr. VP & Chief Technology Officer
• Mr. Johnson Lai, Chief Information Officer
• Ms. Juliet C. Cunningham, VP of Investor Relations
• Mr. Michael Farrington, Sr. VP of Corp. Marketing, Brand & Communication
• Mr. Sean Freeman, Sr. VP of Strategy & Corp. Devel.

What is Chris Barry's approval rating as NuVasive's CEO?

59 employees have rated NuVasive CEO Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among NuVasive's employees.

Who are some of NuVasive's key competitors?

Some companies that are related to NuVasive include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), STERIS (STE), Hologic (HOLX), Insulet (PODD) and Teleflex (TFX).
View all of NUVA's competitors.

What other stocks do shareholders of NuVasive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

Who are NuVasive's major shareholders?

NuVasive's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.70%), Dimensional Fund Advisors LP (2.59%), Paradice Investment Management LLC (2.41%), Goldman Sachs Group Inc. (2.02%), Loomis Sayles & Co. L P (1.46%) and Fisher Asset Management LLC (1.44%). Company insiders that own NuVasive stock include James Christopher Barry, Lucas Vitale, Massimo Calafiore and Matthew Link.
View institutional ownership trends for NuVasive.

Which major investors are selling NuVasive stock?

NUVA stock was sold by a variety of institutional investors in the last quarter, including Pier 88 Investment Partners LLC, Anchor Capital Advisors LLC, Paradice Investment Management LLC, Royal Bank of Canada, The Manufacturers Life Insurance Company , Rothschild & Co. Asset Management US Inc., SG Americas Securities LLC, and Vanguard Group Inc..
View insider buying and selling activity for NuVasive or view top insider-selling stocks.

Which major investors are buying NuVasive stock?

NUVA stock was bought by a variety of institutional investors in the last quarter, including Polar Asset Management Partners Inc., Nuance Investments LLC, Goldman Sachs Group Inc., Leeward Investments LLC MA, Frontier Capital Management Co. LLC, Woodline Partners LP, New York State Common Retirement Fund, and Canada Pension Plan Investment Board.
View insider buying and selling activity for NuVasive or or view top insider-buying stocks.

How do I buy shares of NuVasive?

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $54.08.

How much money does NuVasive make?

NuVasive has a market capitalization of $2.81 billion and generates $1.14 billion in revenue each year. The medical device company earns $-64.09 million in net income (profit) each year or ($0.75) on an earnings per share basis.

How many employees does NuVasive have?

NuVasive employs 2,900 workers across the globe.

Does NuVasive have any subsidiaries?

The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, NuVasive Clinical Services Monitoring Inc., NuVasive Japan KK, NuVasive Specialized Orthopedics Inc., NuVasive Technology International Limited, SafePassage, Simplify Medical, and Vertera Spine.

When was NuVasive founded?

NuVasive was founded in 1997.

What is NuVasive's official website?

The official website for NuVasive is www.nuvasive.com.

How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at (858) 909-1800, via email at [email protected], or via fax at 800-475-9134.